Clinical Microbiology

Biography:

Abstract:

Mycoplasma bovis is a major pathogen, responsible for bovine respiratory diseases worldwide. The present lack of effective control measures leaves cattle owners at considerable perpetual risk of M. bovis outbreaks. In this study, we identified M. bovis secreted immunogenic proteins in silico as potential candidates for novel diagnostic agents and vaccines. We used immunoinformatics to analyze 438 M. bovis proteins previously identified with a label-free proteomics analysis of virulent M. bovis HB0801 (P1) and its attenuated P150 strains. The subcellular localization of these proteins was preliminarily screened and 59 proteins were found to be secreted extracellular proteins. Twenty-seven of these proteins contained a large number of predictive T-cell epitopes presented by major histocompatibility complex (MHC) class I and II molecules. Twenty-two of these 27 proteins had a high number of conformational B-cell epitopes, predicted from the corresponding 3D structural templates, including one unique to P1, two unique to P150, and 19 common to both strains. Five proteins were selected for further validation, and two of these, MbovP274 and MbovP570, were successfully expressed and purified. Both were confirmed to be secretory and highly immunogenic proteins that induced a mouse antibody response, reacted with cattle serum positive for M. bovis infection, and significantly increased the production of interleukin 8 (IL-8), IL-12 and interferon γ(IFN-γ) during the secretion of these three cytokines by both M. bovis mutants of these genes. These results should be useful in the development of novel immunological agents against M. bovis infection.

 

Biography:

Ovidiu Zlatian has completed his PhD at the age of 35 years from University of Medicine and Pharmacy of Craiova, Romania. He is specialist in laboratory medicine and begun working in the microbiology laboratory of the regional hospital of Craiova. Academically, he is in present lecturer at the microbiology department of the  University of Medicine and Pharmacy of Craiova, Romania. He has published more than 25 papers in reputed journals and participated in numerous conferences in the field.    
 

Abstract:

The study aimed to asses correlations between the consumption of antimicrobial agents and the prevalence of bacterial infections and resistance to antimicrobials. We studied 530 endotracheal intubated patients hospitalized in Intensive Care Unit (ICU) of a regional hospital from Romania, collected tracheal secretion samples and analyzed them microbiologically. We performed correlations between aggregated monthly and quarterly resistances with consumption of antimicrobial agents (number of vials/month) in the department. Significant correlations were verified by regression. We detected a strong correlation between the consumption of ciprofloxacin and Pseudomonas resistance to meropenem (r = 0.8565, p = 0.0066) and between consumption of ampicillin and ciprofloxacin resistance (r = 0.6570 , p = 0.0281). The evolution of multiple antibiotic resistance (MAR) index was correlated with the consumption of piperacillin with tazobactam (r = 0.7852, p = 0.0643). Gentamicin resistance of Klebsiella was inversely correlated with ciprofloxacin consumption (r = -0.6311, p = 0.0504) and piperacillin with tazobactam consumption with tigecycline resistance (r = 0.8155, p = 0.0925). The evolution of MAR index of Klebsiella was correlated with the consumption of piperacillin/tazobactam (r = 0.7768, p = 0.0692) and strong consumption of moxifloxacin (r = 0.9734, p = 0.0011). Quarterly index of resistance of Klebsiella correlated strongly with that of Pseudomonas (r = 0.9690 , p = 0.0014 ) , but with significantly different values (Cohen 's d = 1.802, p = 0.011).  The presence of these correlations necessitates monitoring anti-bacterial chemotherapy treatment in ICU and resistance of bacteria involved in pulmonary infections.